by What is the Hemophilia Market Size in 2026?
The global hemophilia market size was valued at USD 12.50 billion in 2025 and is calculated to grow from USD 13.31 billion in 2026 to approximately USD 23.46 billion by 2035, registering a CAGR of 6.50% during the forecast period from 2026 to 2035. The market growth is primarily driven by increasing diagnosis rates and the growing adoption of advanced prophylactic therapies for hemophilia management.
Hemophilia Market Key Takeaways
- North America dominated the global hemophilia market with a share of 42% in 2025.
- Asia-Pacific is expected to grow at the fastest CAGR of 9.5% during the forecast period.
- By type, the hemophilia A segment held a dominant position with a share of 75% in 2025 and is expected to grow at the fastest CAGR of 6% during the forecast period.
- By type, the hemophilia B segment held 20% of the market share in 2025 and is expected to grow at a 5.5% CAGR between 2026 and 2035.
- By treatment, the replacement therapy segment accounted for a considerable revenue share of 50% in the market in 2025.
- By treatment, the gene therapy segment is expected to be the fastest-growing segment with a CAGR of 12.5% between 2026 and 2035.
- By product, the coagulation factor concentrates segment led the global hemophilia market with a share of 55% in 2025 and is expected to grow at the highest CAGR of 7% during the forecast period.
- By product, the recombinant factor segment is expected to expand significantly with a CAGR of 6.5% between 2026 and 2035.
- By route of administration, the intravenous (IV) segment accounted for a considerable revenue share of 55% in the market in 2025.
- By route of administration, the subcutaneous (SC) segment is expected to witness the fastest growth with a CAGR of 9% between 2026 and 2035.
- By end-use, the hospitals segment led the global market with a share of 45% in 2025.
- By end-use, the research institutes segment is expected to be the fastest-growing segment with a CAGR of 8% between 2026 and 2035.
Advancing Hemophilia Care Through Innovative Treatment Solutions
Rare bleeding disorders (RBDs) represent one of the fastest-growing segments within the hemophilia market, driven by increasing awareness, improved understanding of these conditions, and rising diagnosis rates. Advancements in treatment technologies and stronger healthcare initiatives aimed at supporting rare disease management are also contributing significantly to market growth. In addition, government support and financial incentives in developing regions are helping expand access to diagnosis and treatment services.
Pharmaceutical companies are increasingly investing in research and development activities focused on innovative therapies, including long-acting drugs and advanced biologic treatments with reduced administration frequency. Furthermore, rising healthcare expenditure, improving reimbursement policies, and growing collaborations between healthcare providers and biotechnology companies are expected to further accelerate the expansion of the hemophilia market in the coming years.
Hemophilia Market Trends
- High uptake of options for prophylaxis of hemophilia followed by a move to “prevention first” with a more proactive approach and promotion of preventive treatment strategies that reduce bleeds, increase mobility and hospitalisations, and improve life satisfaction for the market.
- Pharmaceutical companies are also playing a role in the market, spending heavily on new therapies that may offer patients a “cure” and enable them to produce their own clotting factors without having to take a drug for their entire life, worldwide.
- Efforts to raise awareness and establish a support programme in the field of rare diseases and early diagnosis are contributing to increasing accessibility to treatment. These efforts have helped minimise the number of undiagnosed cases and enhance care provision for persons with hemophilia around the world.
Key AI Integration in the Hemophilia Market
The healthcare landscape is undergoing a major transformation, with artificial intelligence (AI) playing an increasingly important role in hemophilia diagnosis, treatment planning, and long-term patient management. AI technologies can analyze large volumes of patient data, including genetic information, medical history, imaging results, and treatment responses, to support faster and more accurate clinical decision-making.
In addition, predictive analytics and advanced imaging technologies help identify bleeding risks at an early stage and enable timely medical intervention. These innovations improve patient monitoring, optimize personalized treatment strategies, and reduce the risk of complications associated with delayed diagnosis or treatment in hemophilia care.
Market Dynamics
Driver
Growing Adoption of Non-factor Replacement Therapies
The growing adoption of non-factor replacement therapies is emerging as a significant trend in the hemophilia market, particularly in the treatment of hemophilia A. These therapies are designed to reduce dependence on traditional clotting factor replacement treatments, helping to lower treatment burden and improve overall patient convenience and quality of life.
This innovative treatment approach is especially beneficial for pediatric patients and individuals requiring long-term prophylactic therapy, as it offers easier administration, reduced injection frequency, and improved treatment adherence. The increasing preference for advanced non-factor therapies is expected to support continued growth and innovation in the hemophilia market.
Opportunity
Increasing Research and Development for Novel Therapies
The newly developed markets for hemophilia treatments have huge growth potential in the global market, which is supported by the increasing investment in research and development. The leading pharmaceutical and biotechnology companies are seeking to develop high-tech drug/biotechnology products to fill some of the unmet medical needs and provide improved long-term benefits for patients. The innovative approaches seek to decrease the necessity for treatment, increase the stability of clotting factors, and possibly offer treatments that are of long duration or provide a cure to a patient with hemophilia.
Segment Insights
Type Insights
The Hemophilia A Segment Held a 75% Share for the Hemophilia Market in 2025
The hemophilia A segment dominated the hemophilia market, accounting for a 75% share in 2025, and is expected to grow at a CAGR of 6% during the forecast period. The segment’s growth is primarily driven by the high prevalence of hemophilia A and the increasing demand for advanced treatment approaches worldwide.
Hemophilia A remains the most commonly diagnosed form of hemophilia, with significantly higher diagnosis and treatment rates compared to other types. In addition, the continued availability of recombinant therapies and the growing adoption of proactive prophylactic treatment strategies are further supporting the expansion of this segment.
Region Insights
North America Hemophilia Market Size and Growth 2026 to 2035
The North America hemophilia market size was valued at USD 5.25 billion in 2025 and is projected to reach approximately USD 9.97 billion by 2035, expanding at a CAGR of 6.62% during the forecast period from 2026 to 2035.
Which Factors Drive the Hemophilia Market in North America?
North America held a major market share of 42% in 2025, owing to the presence of well-established specialized disease treatment centers, patient access to biologics, and the development of end-user adoption of emerging gene therapies for controlling chronic diseases. The rising recognition of therapeutic techniques that can be employed in early detection and prevention is driving the market. In addition, government initiatives and appropriate insurance coverage are making more expensive treatments for hemophilia more available in more countries. The Food and Drug Administration (FDA) and other important universities and organisations are also heavily investing in research and development activities in the field.
U.S. Hemophilia Market Size and Growth 2026 to 2035
The U.S. hemophilia market size was valued at USD 3.94 billion in 2025 and is projected to reach approximately USD 7.53 billion by 2035, registering a CAGR of 6.69% during the forecast period from 2026 to 2035.
U.S. Market Trends
The U.S. represents a large market in North America, owing to the presence of many pharmaceutical companies, availability of advanced healthcare facilities and high expenditure incurred on healthcare in the region. Hemophilia patients have access to specialized treatment, genetic counselling and access to cutting-edge treatment at frequent hemophilia treatment centers available in the country. Favorable regulatory processes and the growing acceptance of a speedy commercialization of advanced therapies are due to solid reimbursement support.
How is Asia-Pacific Growing in the Hemophilia Market?
Asia-Pacific held 18% of the market share in 2025 and is expected to grow at the fastest CAGR of 9.5% during the projection period, due to the increase in healthcare facilities, the rising healthcare expenses, and enhanced awareness of rare bleeding disorders. Advanced treatment solutions are required in countries such as China and India to diagnose cases of hemophilia. Governments and medical bodies are engaged in medical awareness campaigns to ensure access to medical centers specializing in medical management to address medical needs. Market growth is also being supported by the increasing use of clotting factor replacement therapies, as well as the use of biologic treatments.
Top Companies in the Hemophilia Market
- Ferring Pharmaceuticals specializes in developing innovative therapies for rare diseases and bleeding disorders, including treatments that support improved patient outcomes in hemophilia care. The company focuses on advancing biologic and plasma-derived therapeutic solutions.
- Baxter International provides a wide range of healthcare products, including hemophilia therapies and clotting factor treatments. The company is known for its focus on biotechnology, patient care, and advanced therapeutic solutions.
- Shire, now part of Takeda Pharmaceutical Company, has a strong presence in the hemophilia market through innovative therapies for bleeding disorders and rare diseases. The company emphasizes long-term prophylactic treatments and patient-centered care.
- Octapharma develops and manufactures plasma-derived and recombinant therapies for hemophilia and other rare bleeding disorders. The company focuses on improving treatment safety, efficacy, and accessibility worldwide.
- Hematologic Technologies specializes in coagulation research products and diagnostic solutions related to blood disorders. The company supports advancements in hemophilia research, drug development, and laboratory testing technologies.
- Sobi focuses on rare diseases and provides innovative therapies for hemophilia management and bleeding disorders. The company is recognized for its long-acting hemophilia treatments and patient support initiatives.
- Medi-Pharm develops healthcare and specialty pharmaceutical products that support advanced therapeutic applications. The company is involved in expanding treatment accessibility and innovation across specialized healthcare segments.
- Kedrion Biopharma manufactures plasma-derived therapies for rare and serious diseases, including hemophilia and immune disorders. The company focuses on delivering safe, high-quality biologic treatments globally.
- Biogen develops innovative therapies for neurological and rare diseases while expanding research capabilities in advanced biologics and precision medicine. The company also invests in technologies supporting next-generation treatment development.
Check this report to: ATM Managed Services Market
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com
Get Sample : https://www.precedenceresearch.com/sample/8416
You can place an order or ask any questions. Please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344
